From the American Academy of Ophthalmology

First-year results of two phase 3 studies comparing intravitreal aflibercept, monthly or every two months, with monthly ranibizumab show that aflibercept can potentially decrease the treatment and compliance burden of anti-VEGF treatment. Results show aflibercept dosed monthly or every two months after three initial monthly doses resulted in similar visual and anatomic outcomes as ranibizumab dosed monthly, and with a similar safety and tolerability profile.  Ophthalmology, December 2012